Explore the Agenda
7:30 am Morning Check-In & Coffee
8:15 am Chair’s Opening Remarks
Transforming a Decade of Liquid Biopsy Progress into Routine Clinical Impact for Every Patient
8:20 am The Real-World Impact of Liquid Biopsy: The Patient Voice
As we open the 10th Liquid Biopsy for Precision Oncology Summit, we set aside the innovation & technology to begin with the perspective that matters most: the patient voice.
8:30 am 10 Years of Liquid Biopsy: Igniting a New Era in Precision Oncology
- Highlighting key scientific, technological, and regulatory milestones that have shaped the past decade of liquid biopsy innovation
- Identifying the most pressing challenges that still hinder broader adoption across trial phases, tumor types, and clinical settings
- Outlining the next strategic priorities needed to ensure liquid biopsies become a standard, validated tool for patient selection, monitoring, and treatment optimization in every clinical trial
9:00 am Presentation Details to be Announced
9:30 am Confronting Complexity: Defining the Next Decade of Liquid Biopsy in Precision Oncology
- Confronting the translational hurdles that limit liquid biopsy adoption in drug development, from tumor heterogeneity and assay sensitivity to cost and trial feasibility
- Integrating emerging technologies such as methylation profiling and AI with the rigor required for clinical validation in oncology trials
- Defining how pharma decision-making will shape the path from exploratory assays to scalable, routine tools that deliver real patient impact
10:00 am Presentation Details to be Announced
10:30 am Morning Break & Speed Networking
As the liquid biopsy community comes together for the 10th anniversary meeting, this dedicated session is designed to help you build meaningful new connections. All attendees will have the chance to meet peers across pharma, biotech, diagnostics and academia, ensuring valuable relationships that extend beyond the summit.
Standardizing Liquid Biopsies to Drive Reliable, Scalable Adoption Across Trials & Clinical Practice
11:30 am Interactive Session: Breaking Down Standardization Barriers Through Consistent Terminology & Metrics to Boost Liquid Biopsy Adoption
- What are the key roadblocks that continue to hinder standardization across liquid biopsy platforms, assays, and reporting?
- Establishing shared definitions, thresholds, and response criteria to align a fragmented field
- Building a practical roadmap for standardization, including actionable milestones and measurable impact to track progress and build confidence
12:00 pm Presentation Details to be Announced
12:30 pm Panel Discussion: Bridging the Gap from Innovation to Access by Aligning Standardization, Policy & Reimbursement for Liquid Biopsy
- Uncovering how inconsistent definitions, metrics, and data standards are hindering payer confidence and policy support for liquid biopsy
- Exploring the role of pre-competitive collaboration in driving standardization to unlock broader reimbursement and clinical adoption
- Identifying immediate policy actions and evidence needs to align stakeholders and accelerate access to serial testing and early detection
1:00 pm Presentation Details to be Announced
1:30 pm Lunch Break & Networking
Track A: Preclinical Development & Early Translational
Embedding Robust Analytical Validation into Translational Studies to Drive Clinical Success – Chaired by
2:20 pm Advancing Precision Oncology through ctDNA Dynamics
- Exploring how ctDNA dynamics, including methylation patterns, can be leveraged to evaluate therapeutic response and inform treatment decisions
- Discussing the translational value of ctDNA analyses in uncovering mechanisms of resistance and guiding precisionoriented therapies
- Highlighting opportunities to integrate ctDNA into routine clinical workflows to better monitor tumor evolution and improve outcomes for patients with hard-to-treat cancer
2:45 pm Presentation Details to be Announced
3:15 pm Fireside Chat: Overcoming Sensitivity & Specificity Challenges to Deliver Reliable Liquid Biopsy Results at Scale
- Defining and achieving the optimal analytical thresholds for sensitivity and specificity in line with intended clinical use – how sensitive is too sensitive?
- Discussing strategies to minimize CHIP related false positives and false negatives without compromising turnaround time or trial feasibility
- Refining analytical validation data strategies to support regulatory submissions, companion diagnostic partnerships, and confident clinical decision-making
3:45 pm Presentation Details to be Announced
Track B: Clinical Development & Commercialization
Driving Clinical Validation to Enhance Decision-Making & Accelerate Diagnostic Approval – Chaired by
2:20 pm Utility of ctDNA for Response Assessment of Solid Tumors Treated with Personalized Cancer Immunotherapy
- Demonstrating how ctDNA identifies molecular response and tracks response duration where MRI-based RECIST lacks clarity
- Leveraging ctDNA alongside imaging to enable earlier and more accurate detection of therapeutic benefit in second-line advanced HCC
- Using ctDNA-guided monitoring as an exploratory endpoint to inform trial design, optimize treatment strategies, and lay the groundwork for broader regulatory acceptance
2:45 pm Presentation Details to be Announced
3:15 pm Panel Discussion: Clinically Validating Liquid Biopsies for Early Clinical Endpoints to Enhance Patient Selection & Monitoring
- What evidence and study designs are most critical to clinically validate liquid biopsies as early endpoints in trials, and how do these differ across indications?
- How can validated liquid biopsy endpoints improve patient selection and ongoing monitoring to accelerate therapeutic development and decision-making?
- What regulatory, operational, and data-standardization challenges still need to be addressed to ensure liquid biopsy endpoints are trusted and broadly adopted?
3:45 pm Presentation Details to be Announced
4:15 pm Afternoon Networking Break
Track A: Preclinical Development & Early Translational
Harnessing Novel AI, Methylation & Cutting-Edge Technology to Unlock Unprecedented Liquid Biopsy Insights
5:15 pm Leveraging Mutation & Methylation-Based ctDNA Profiling to Capture Tumor Heterogeneity & Enhance Clinical Readouts
- Demonstrating how broader ctDNA panels extend beyond single-gene tracking in advanced cancer, as a surrogate readout of clinical efficacy and to reveal tumor heterogeneity and evolving drivers of resistance
- Lessons from applying methylation-based sequencing approaches in oncology trials, including challenges in data interpretation and reporting
- Opportunities and limitations of integrating fragmentomics insights derived from methylation data to complement response monitoring in advanced disease
5:40 pm Underpinning the Value of Urine for Predictive & Monitoring Biomarkers in Bladder Cancer
- Comparing utDNA with traditional ctDNA for monitoring disease burden and detecting recurrence
- Optimizing assay sensitivity, specificity & turnaround time for real-world clinical use
- Leveraging longitudinal utDNA analysis to guide treatment decisions and improve patient outcomes
Track B: Clinical Development & Commercialization
Seamlessly Integrating Liquid Biopsies into Clinical Trials to Streamline Multi- Vendor & Operational Barriers
5:15 pm Building Standardized ctDNA & MRD Strategies to Accelerate Clinical Development of Immune-Based Therapies
- Examining how ctDNA and MRD assays can serve as regulatory-acceptable biomarkers and support commercialization of CAR-T and T-cell engager therapies
- Addressing harmonization challenges across assay platforms and how standardization can streamline late-phase trials and companion diagnostic development
- Exploring opportunities for integrated, multi-omic bloodbased assays to provide scalable solutions that meet payer, regulatory, and clinician expectations
5:40 pm Liquid Biopsy Across the Drug Lifecycle: Discovery, Differentiation & Adoption
- Showing how Amgen leverages ctDNA and other modalities across discovery, clinical development, and commercialization to accelerate differentiation, regulatory approvals, and market adoption
- Highlighting case studies where ctDNA and liquid biopsy analyses informed dose selection, early efficacy readouts, and patient stratification, directly supporting faster decisionmaking and clinical success
- Discussing how Amgen generates the biomarker evidence base needed for regulators, payers, and clinicians to embrace liquid biopsy as a standard tool in advancing precision medicine
6:05 pm Drinks Reception, Hosted by Foundation Medicine
7:05 pm Evening Engager, Hosted by Foundation Medicine
This exclusive session offers pharma leaders a unique opportunity to engage directly with Foundation Medicine and each other in a focused networking environment. Building on the day’s discussions, the engager will spark conversation on the evolving role of liquid biopsy in oncology and provide a platform to explore future partnerships, collaborations and strategic priorities.
Please note: Attendance at this session is subject to availability and partner approval